Figure 1.

(A) Structure of previously reported RPA inhibitors targeting RPA–DNA interaction.²³⁻²⁶ (B) Schematic representation of SAR design rationale: a large space-filling pocket surrounding Ring A of compound 4 and amino acid residues surrounding the alkyl carboxylic acid side chain which can be extended toward the solvent-exposed region for further structural optimization. [Compound 4 hydrogen bond interaction with Ser392 and Arg382 is indicated with the dashed magenta line, π–π stacking interactions with Trp361 and Phe386 are shown in solid magenta dumbbell, and salt-bridge interactions with Lys313 are shown in dashed two-sided magenta arrow.]